IDEX (IEX) Stock Forecast & Price Target

IDEX is positioned for durable outperformance because its portfolio is increasingly tilted toward advantaged markets such as data centers, semiconductors, space/defense, pharma, and water, where 2Q26 organic orders rose 28% year over year and the book-to-bill reached 1.16x. Management and analysts also highlighted stronger 2026 and 2027 growth assumptions, with 2026E adjusted EPS raised to $8.80 and 2027E to $9.40, supported by productivity gains, tariff-refund benefits, and improving margins. Financial discipline further reinforces the outlook, as 2Q26 free cash flow converted at 103% of net income, net leverage stayed low at 1.3x, and a $77M share repurchase plus a strong liquidity position provide room for continued accretive capital deployment.

IDEX is exposed to multiple fundamental headwinds that could pressure growth and margins, including tariff-related cost inflation that may not be fully offset by pricing and demand weakness in shorter-cycle businesses. A prolonged inventory reset in higher-margin end markets such as life sciences and agriculture, along with volatile public funding for municipal water, fire and rescue, and health and science technologies, could further dampen volumes and reduce visibility. With $3.5 billion in revenue in 2025, the company also faces FX risk if the USD strengthens, while any missteps in M&A or a sustained decline in industrial spending would add to downside.